General Biotechnology

The Patent Dance Playbook Is BrokenHeres How Biologics Applicants Can Win Anyway
If youve been anywhere near biologics patent litigation lately, youve heard the phrase: the patent dance. Its the choreography that determines who gets to see what, when, …

Patent cliffs dont just threaten revenuethey can quietly reshape your entire supply chain.
For years, patent expiry has been treated like a legal milestone: a date on a calendar, a headline in a quarterly report, a trigger for generic competition. Bu…

Generic drug makers are facing a quiet margin crisisand its not just pricing pressure in the abstract. Its a stack of operational, regulatory, and market-structure problems hitting at the same time, turning what used to be a predictable business into a…

The FDA Orange Book is supposed to be a reference. But for generic drug makers, its a playbook.
If youve ever wondered how some generic companies seem to arrive at market faster than othersoften right when exclusivities expireheres the uncomfortable tr…

Biopharma hiring is brokennot because talent is scarce, but because the org chart is often a guess.
Most teams still recruit like IP is a side quest. They post roles for IP strategy, patent prosecution, or licensing, then hope the right candidate can t…

The generic cliff doesnt just happen. Pharma engineers it.
For years, the story has been told as a simple timeline: patents expire, generics arrive, revenues fall. But anyone watching the industry closely knows the real plot is more deliberateand mor…

Patent thickets are the new moatand biologics are the new battleground.
If youve ever wondered why some blockbuster biologic drugs seem to face a wall of delays long after the science is proven and the market is ready for competition, the answer is o…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most companies dont lose to competitorsthey lose to time.
Time spent waiting for a patent to ripen into enforceable rights. Time spent paying licensing fees that could have been avo…

Russias VED SSM lists are the kind of policy detail that looks boringuntil youre the one trying to launch a generic on time.
Heres the reality: in markets where regulatory timelines are tightly coupled to patent status, the calendar becomes a competiti…

Pharma IP teams are used to thinking in patent years. But in Russia, the clock can movefastand the consequences are immediate.
Russias patent-term extension landscape is changing in ways that can make or break market exclusivity, pricing strategy, and …